Brief: Immunome Announces Positive Topline Results From Phase 3 Ringside Trial Of Varegacestat In Patients With Desmoid Tumors
15/12/2025 12:19
Dec 15 (Reuters) - Immunome Inc IMNM.O: IMMUNOME ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 RINGSIDE TRIAL OF VAREGACESTAT IN PATIENTS WITH DESMOID TUMORS IMMUNOME INC - VAREGACESTAT IMPROVES PROGRESSION-FREE SURVIVAL IN PHASE 3 TRIAL IMMUNOME INC - VAREGACESTAT ACHIEVES 56% OBJECTIVE RESPONSE RATE IN TRIAL IMMUNOME INC - VAREGACESTAT WELL TOLERATED WITH MANAGEABLE SAFETY PROFILE IMMUNOME INC - NDA SUBMISSION FOR VAREGACESTAT PLANNED FOR Q2 2026 Source text: ID:nBwbNM1WXa Further company coverage: IMNM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunome
See all newsBrief: Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Immunome climbs as Stifel initiates coverage